Precision Oncology in Hepatopancreatobiliary Cancer Surgery
TE Newhook, S Tsai… - Surgical Oncology …, 2024 - surgonc.theclinics.com
Precision Oncology in Hepatopancreatobiliary Cancer Surgery - Surgical Oncology Clinics
Skip to Main Content Advertisement Surgical Oncology Clinics Log in Register Log in …
Skip to Main Content Advertisement Surgical Oncology Clinics Log in Register Log in …
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
F Facchinetti, Y Loriot, F Braye, D Vasseur… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …
[HTML][HTML] A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary
mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective …
mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective …
[HTML][HTML] Targeted therapies in biliary tract cancer—when precision becomes imprecise
CJ O'Rourke, JV Schou, JB Andersen… - ESMO Gastrointestinal …, 2024 - Elsevier
Advanced biliary tract cancers (BTCs) have gained notoriety among gastrointestinal tumours
for their comparatively high incidence of actionable alterations and their compelling benefit …
for their comparatively high incidence of actionable alterations and their compelling benefit …